Expanding Understanding
For the TAXUS III In-Stent Restenosis Feasibility Trial data in portable document format,
click here.
| Objective: |
Evaluate feasibility of slow rate TAXUS® NIR® release Paclitaxel-Eluting Stent to treat and reduce recurrent restenosis of previously implanted stents. |
| Number of Patients: |
28 |
| Number of Sites: |
2 |
| Lesions: |
In-stent restenosis, < 30 mm length, 3.0 and 3.5 mm diameters |
| Stent Platform: |
NIR® Conformer 15 mm |
| Release Kinetics: |
Slow |
| Primary Endpoint: |
30-day MACE |
| P.I. and Co-P.I.: |
E. Grube, M.D. and P. Serruys, M.D. |
| Status: |
Enrollment complete |
NIR is a registered trademark of Medinol, Ltd. Jerusalem, Israel.
